Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy.

Trial Profile

Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Helsinn
  • Most Recent Events

    • 24 Mar 2012 Actual end date (Apr 2011) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 06 Aug 2011 This trial is recruiting in Czech Republic, Germany and has completed in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top